Douglas Tremblay

Nov 12, 2024 | nature.com | Douglas Tremblay |Clifford M. Csizmar |Courtney DiNardo |Danielle Hammond |Tapan M Kadia |Farhad Ravandi | +10 more

Chronic myelomonocytic leukemia (CMML) is a rare hematologic malignancy with overlapping features of myelodysplastic neoplasm (MDS) and myeloproliferative neoplasms characterized by peripheral blood monocytosis [1]. There is a predisposition for transformation to acute myeloid leukemia (AML), termed CMML with blast transformation (CMML-BT) [2, 3].

Aug 6, 2024 | newsbreak.com | Douglas Tremblay

By signing up for our newsletter, you agree to our Terms of Use and Privacy Policy

Aug 6, 2024 | targetedonc.com | Douglas Tremblay

Douglas Tremblay, MD, assistant professor of medicine at the Icahn School of Medicine at Mount Sinai, discusses the different cytoreduction approaches available to patients with myeloproliferative neoplasms (MPNs), specifically essential thrombocytopenia (ET) and polycythemia vera (PV), and the safety profiles of these agents. Transcription:0:09 | The different set of cytoreductive approaches available for patients depends on which disease you have.

Jan 31, 2024 | targetedonc.com | Douglas Tremblay

Douglas Tremblay, MD, assistant professor of medicine at the Icahn School of Medicine at Mount Sinai, discusses the factors which influence the decision to recommend cytoreduction for patients with essential thrombocytopenia (ET) and polycythemia vera (PV). According to Tremblay, deciding when to start cytoreductive therapy in patients with chronic myeloproliferative neoplasms (MPN) patients like those with PV and ET hinges on accurate risk assessment.

Jan 8, 2024 | targetedonc.com | Douglas Tremblay

Douglas Tremblay, MD, assistant professor of medicine at the Icahn School of Medicine at Mount Sinai, discusses the use of cytoreductive therapy and potential benefits and risks of cytoreduction for patients with essential thrombocytopenia (ET) and polycythemia vera (PV). According to Tremblay, the primary approach that is used to prevent thrombosis in certain disease states involves cytoreductive therapy.